# EDGAR Filing Document

**Accession Number:** 0001445499
**File Stem:** 0000950170-23-000468
**Filing Date:** 2023-1
**Character Count:** 30341
**Document Hash:** fc56800c277b3ede3008c07720f0a5b0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-000468.hdr.sgml**: 20230109

**ACCESSION NUMBER**: 0000950170-23-000468

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 41

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230109

**DATE AS OF CHANGE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IMPEL PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001445499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263058238
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0426

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40353
- **FILM NUMBER:** 23516805

**BUSINESS ADDRESS:**
- **STREET 1:** 201 ELLIOTT AVE. W
- **STREET 2:** SUITE 260
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98119
- **BUSINESS PHONE:** 206-568-1466

**MAIL ADDRESS:**
- **STREET 1:** 201 ELLIOTT AVE. W
- **STREET 2:** SUITE 260
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98119

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMPEL NEUROPHARMA INC
- **DATE OF NAME CHANGE:** 20080917

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 09, 2023<br>

------

IMPEL PHARMACEUTICALS INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40353 | 26-3058238 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 201 ELLIOTT AVE. W, SUITE 260, |  |  |
| Seattle**,** Washington |  | 98119 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 206 568-1466<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 Par Value Per Share | IMPL | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On January 9, 2023, the Company updated its corporate presentation, which it intends to use as part of investor presentations. A copy of the presentation is attached to this Report as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

This information contained in this Current Report on Form 8-K, including the attached Exhibit 99.1, shall be deemed "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Number** | **Description** |
| 99.1 | [<u>Presentation of Impel Pharmaceuticals Inc.</u>](impl-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **IMPEL PHARMACEUTICALS INC.**  |
| Date: | January 9, 2023 | By:  | /s/ John Leaman |
|  |  |  | John Leaman<br>Chief Financial Officer |

---

------

## Exhibit 99.1

![Slide 1](impl-ex99_1s1.jpg)

Impel Pharmaceuticals Inc. Corporate and Business Update January 2023 Exhibit 99.1

------

![Slide 2](impl-ex99_1s2.jpg)

Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, business plans and objectives, timing and success of our planned development activities, our ability to obtain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, potential growth opportunities, competitive position, industry environment and potential market opportunities. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These factors, together with those that may be described in greater detail in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other reports the company files from time to time with the Securities and Exchange Commission, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

------

![Slide 3](impl-ex99_1s3.jpg)

The Impel Investment Opportunity POD® Technology: Clinically Validated and Broad Utility Unique approach targeting upper nasal space; broad disease area applicability Trudhesa™ - Significant Commercial Opportunity in Migraine Market Large, growing and dynamic market with significant unmet need Highly Targeted Commercialization Strategy Initial 60-person salesforce; targeting 8K physicians (35% of Market Rxs) Strong market access footprint – 80% commercial lives covered Increased salesforce by 50% in July 2022 based on launch momentum INP105: Poised to Fill a Major Unmet Need Targeted for acute treatment of agitation and aggression in autism Phase IIa PoC Study (CALM 201) initiated in July; Results in 2H 2023 Proven and Experienced Leadership Team

------

![Slide 4](impl-ex99_1s4.jpg)

The Trudhesa Clinical Profile

------

![Slide 5](impl-ex99_1s5.jpg)

Trudhesa PK Levels – Comparable to IV DHE; Surpassed Migranal AUC in the First Two Hours – Thought to Be Critical to DHEEfficacy and Tolerability Trudhesa Delivers Comparable Blood Levels vs. IV DHE vs. MIGRANAL 4x increase in Cmax 3x increase in AUC Much improved consistency of dosing, similar to IV infusion Similar blood levels (20 mins - 48 hours) without early Cmax spike associated with nausea & vomiting Treatments

------

![Slide 6](impl-ex99_1s6.jpg)

Trudhesa – Impressive Efficacy from Phase III Study Migraines Treated 4th12 weeks 3rd12 weeks 2nd12 weeks 1st12 weeks 2,559 1,736 502 476 38% 35% 38% 34% 38% Percentage of subjects with 2 Hr Pain Freedom First Dose TRUDHESA 52% Percentage of subjects with 2 Hr MBS Freedom Consistent 2 Hr Pain Freedom over 5,273 Migraines Treated 74% of Enrolled Patients Continued Through 24 Weeks and 90% Enrolled Through 52 Week Extension

------

![Slide 7](impl-ex99_1s7.jpg)

Trudhesa – Impressive Migraine Relapse-free Data Consistent 2 Hr Pain Freedom over 5,273 Migraines Treated 86% of patients with migraines achieved pain freedom at 2 hours and are migraine and rescue med free at 48hrs % of TRUDHESA Patients Not Requiring Rescue Medor Recurrence of Migraine at 24 and 48 Hours (Of Those Pain Free at 2 Hours) \*by week 21-24.

------

![Slide 8](impl-ex99_1s8.jpg)

Trudhesa – Impressive Reduction in Hospitalizations, ER and Urgent Care Visits \* EAER is a standardized metric used by payors to judge the effectiveness of a medication in lowering medical costs ~73% Reduction in ER VisitsAchieving a 100% Reduction in Hospitalizations / Urgent Care Provides Tangible Economic Value to Payors

------

![Slide 9](impl-ex99_1s9.jpg)

Trudhesa Performance Update

------

![Slide 10](impl-ex99_1s10.jpg)

Migraine: Strong Market Growth but Ongoing Unmet Need Migraine – Large Growing Market with Significant Unmet Need Despite New Treatment Innovations Nurtec ODT and Ubrelvy Patient Claims Show ~60% Therapy Abandonment 90 Day Post Start Source: Symphony Health Patient Claims (Mar'20 – Dec'21) 57% 66% 27M 24M +13% 30M +11% 88% 12% 81% 19% 75% 25% Source: Symphony Health

------

![Slide 11](impl-ex99_1s11.jpg)

Trudhesa – Robust Prescription Growth in 2022 Launch Focus: Driving Rapid Adoption and Prescription Momentum +48% Source: Symphony Add Q3 to date? +52% 2022 Normalized TRx = 58,420

------

![Slide 12](impl-ex99_1s12.jpg)

Continued Prescription Growth and Share Penetration into Q4 Trudhesa Average nTRx Per Week Source: Symphony nTRx data Acute Branded Market = Trudhesa, Nurtec ODT, Ubrelvy Trudhesa nTRx Share of Acute Branded Market Among Prescribers

------

![Slide 13](impl-ex99_1s13.jpg)

Increased Salesforce Leading to Acceleration of New Prescriptions Launch Focus: Driving Rapid Adoption and Prescription Momentum Source: Symphony +58%

------

![Slide 14](impl-ex99_1s14.jpg)

Sales Force Expansion Allowing for Additional HCP Discussions Resulting in NBRx Growth Symphony Trudhesa New to Brand Rx Source: Symphony NBRx data \* Excludes current vacancies (n=7)

------

![Slide 15](impl-ex99_1s15.jpg)

Trudhesa Adoption Showing Continued Growth Trudhesa Cumulative Prescribers Since Launch Source: Internal Pharmacy Data

------

![Slide 16](impl-ex99_1s16.jpg)

Increasing Reimbursement and Consistently High Refill Rates Percent of Rx Shipments Reimbursed Source: Internal Pharmacy Data Source: Internal Pharmacy Data Trudhesa: Consistent, High Refill Rates

------

![Slide 17](impl-ex99_1s17.jpg)

Trudhesa Increasingly Being Added to Gepant Patients to Provide Additional Efficacy 61% Gepant Patient Claims Show ~60% Therapy Abandonment 90 Day Post Start ~71% of Trudhesa Patients Being Added to Existing Therapy Source: Symphony Patient Level Claims Data (YTD Aug'22) Source: Symphony Patient Level Claims Data Dropped Off Switched Away Continuing Added to Trudhesa Switched From Other Therapy Switch From Other Therapy Added On to Existing Therapy ~40% of Trudhesa Patients Being Either Switched From or Added to Gepants Source: Symphony Patient Level Claims Data

------

![Slide 18](impl-ex99_1s18.jpg)

Pipeline Growth Opportunities

------

![Slide 19](impl-ex99_1s19.jpg)

INP105 – Potential to Provide Rapid and Non-Traumatic Acute Treatment of Agitation and Aggression in Autism 0.6m ASD Patients with Agitation 29m Severe Episodes 7m PRN Treated 28m Moderate Episodes 5.7m PRN Treated 74m Mild Episodes 5.3m PRN Treated Patients Agitation/ Aggression Episodes Treated PRN Over 100m annual agitation/aggression episodes from ~600k children and adolescents with ASD Vast majority of episodes are not treated with PRN medications leaving HCP's to adjust daily/standing medications Current options require daily dosing, tend to produce weight gain, and increase diabetes risk; require close monitoring PRN dosing of INP105 may provide the efficacy of olanzapine while sparing patients many of the tolerability and safety issues seen with daily use Caregiver administration brings control to families in home setting Non-invasive administration when meds are needed Episode may be aborted before escalation Source: ZS Associates Market Research / Market Sizing (May'22)

------

![Slide 20](impl-ex99_1s20.jpg)

INP105 – Acute Treatment of Agitation in Autism \*Nominal times used for mean plot INP105 - SIMILAR PK TO OLANZAPINE INJECTION, BUT FASTER TO PEAK BLOOD LEVELS Rapid Tmax, Cmax and AUC of INP105 matches 5mg IM olanzapine INP105 enables rapid systemic absorption without an injection INP105 was well tolerated and led to similar exposure and faster plasma uptake than IM injection Phase 1 Conclusions Phase 1 PK Profile vs. IM CALM 201 Clinical Study Objective CALM 201 studies INP105 in adolescents with Autism Study Design Single dose, placebo controlled, double blind study of safety and efficacy through multiple scales Study Timelines Study initiation – July 2022 Pilot phase completed – Q4 2022 Last Patient, Last Visit – Q2 2023 Full Study Results – 2H 2023 INP105 had rapid onset of action observed in healthy volunteers INP105 may be the first rapid acting olanzapine to treat agitation in multiple indications

------

![Slide 21](impl-ex99_1s21.jpg)

Overall Business Summary

------

![Slide 22](impl-ex99_1s22.jpg)

Corporate Business Overview – Summary Trudhesa growth continues with an expanding high value prescriber base Normalized Total Rx's increased in Q4 by ~18% vs. Q3 Trudhesa nTRx share of the acute branded market now over ~4% among prescribers Increased cumulative LTD Trudhesa prescribers by ~23% vs. Q3 Field force expansion leading to improvement in leading indicators ~58% increase in normalized New Prescriptions in Q4 vs. Q2 (pre-expansion) Increased efficiency leading to significant increases across both new and existing territories Stable GTN levers with net price evolution in clear view with quickstart/bridge adjustments INP105 Phase IIa CALM 201 study progressing with results expected 2H2023

------

![Slide 23](impl-ex99_1s23.jpg)

Appendix

------

![Slide 24](impl-ex99_1s24.jpg)

Surveyed Trudhesa Patients Provide High Rating to Key Brand Attributes and Saw Trudhesa as Better Option vs Prior Abortive Therapy\* \* Source: Ipsos Patient Survey via Digital Pharmacy

------

![Slide 25](impl-ex99_1s25.jpg)

Trudhesa Increasingly Being Added to Gepant Patients to Provide Additional Efficacy ~71% of Trudhesa Patients Being Added to Existing Therapy Source: Symphony Patient Level Claims Data (YTD Aug'22) Dropped Off Switched Away Continuing Added to Trudhesa Switched From Other Therapy ~30-40% of Trudhesa Patients Being Either Switched From or Added to Gepants Source: Symphony Patient Level Claims Data

------

![Slide 26](impl-ex99_1s26.jpg)

Anticipate Robust Gepant Market Growth Thru 2025 Gepant Market to reach ~4.5m nTRx's in 2023 and increase to ~8m in 2025 Nearly 1m Gepant Patients in 2023 Trudhesa share in 2022 = ~1% Source: Symphony Health

------

![Slide 27](impl-ex99_1s27.jpg)

Neurologists Project a Sizable Increase in Trudhesa's Brand Share Current 95% Projected 95% 89% 93% User Base Quantitative data collected from 75 US neurologists between June 1st and June 5th , 2022 Qualitative data collected from 8 US neurologists between June 13th and 17th, 2022 52% 73% Projected Peak share Current and Projected Self-Reported RMS Patient Share Mean % of patients 12.0%

### Attached PDF Documents

**Attachment 1:** `impl-ex99_1.pdf`

Exhibit 99.1

# Impel Pharmaceuticals Inc.
## Corporate and Business Update

January 2023

1

Impel
PHARMACEUTICALS

# Forward-Looking Statements

This presentation and the accompanying oral commentary contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, business plans and objectives, timing and success of our planned development activities, our ability to obtain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, potential growth opportunities, competitive position, industry environment and potential market opportunities.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. These factors, together with those that may be described in greater detail in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other reports the company files from time to time with the Securities and Exchange Commission, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.

In addition, statements that 'we believe' and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this presentation, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

2

Impel  
PHARMACEUTICALS

# The Impel Investment Opportunity

POD® Technology: Clinically Validated and Broad Utility

- Unique approach targeting upper nasal space; broad disease area applicability

TrudhesaTM - Significant Commercial Opportunity in Migraine Market

- Large, growing and dynamic market with significant unmet need

Highly Targeted Commercialization Strategy

- Initial 60-person salesforce; targeting 8K physicians (35% of Market Rxs)
- Strong market access footprint - 80% commercial lives covered
- Increased salesforce by 50% in July 2022 based on launch momentum

INP105: Poised to Fill a Major Unmet Need

- Targeted for acute treatment of agitation and aggression in autism
- Phase IIa PoC Study (CALM 201) initiated in July; Results in 2H 2023

Proven and Experienced Leadership Team

3

Impel
PHARMACEUTICALS

# The Trudhesa Clinical Profile

4

Impel
PHARMACEUTICALS

# Trudhesa PK Levels - Comparable to IV DHE; Surpassed Migranal

![img-0.jpeg](img-0.jpeg)

Trudhesa Delivers
Comparable Blood Levels

vs. IV DHE

- Similar blood levels (20 mins - 48 hours) without early Cmax spike associated with nausea & vomiting

vs. MIGRANAL

- 4x increase in Cmax
- 3x increase in AUC
- Much improved consistency of dosing, similar to IV infusion

5

Impel
PHARMACEUTICALS

# Trudhesa - Impressive Efficacy from Phase III Study

**74%** of Enrolled Patients Continued Through 24 Weeks and **90%** Enrolled Through 52 Week Extension

![img-1.jpeg](img-1.jpeg)

impel
PHARMACEUTICALS

# Trudhesa - Impressive Migraine Relapse-free Data

% of TRUDHESA Patients Not Requiring Rescue Med
or Recurrence of Migraine at 24 and 48 Hours
(Of Those Pain Free at 2 Hours)

![img-2.jpeg](img-2.jpeg)

7

impel
PHARMACEUTICALS

# Trudhesa - Impressive Reduction in Hospitalizations, ER and Urgent Care Visits

![img-3.jpeg](img-3.jpeg)

~73% Reduction in ER Visits

Achieving a 100% Reduction in Hospitalizations / Urgent Care Provides Tangible Economic Value to Payors

* EAER is a standardized metric used by payors to judge the effectiveness of a medication in lowering medical costs

8

impel
PHARMACEUTICALS

# Trudhesa Performance Update

9

Impel
PHARMACEUTICALS

# Migraine: Strong Market Growth but Ongoing Unmet Need

Migraine - Large Growing Market with Significant Unmet Need Despite New Treatment Innovations

![img-4.jpeg](img-4.jpeg)

Source: Symphony Health

Nurtec ODT and Ubrelvy Patient Claims Show ~60% Therapy Abandonment 90 Day Post Start

![img-5.jpeg](img-5.jpeg)

Source: Symphony Health Patient Claims (Mar'20 - Dec'21)

10

impel
PHARMACEUTICALS

# Trudhesa - Robust Prescription Growth in 2022

## Launch Focus: Driving Rapid Adoption and Prescription Momentum

![img-0.jpeg](img-0.jpeg)

![img-1.jpeg](img-1.jpeg)

Source: Symphony

11

**impel**  
PHARMACEUTICALS

# Continued Prescription Growth and Share Penetration into Q4

![img-2.jpeg](img-2.jpeg)

Source: Symphony nTRx data
Acute Branded Market = Trudhesa, Nurtec ODT, Ubrelvy

![img-3.jpeg](img-3.jpeg)

12

impel
PHARMACEUTICALS

# Increased Salesforce Leading to Acceleration of New Prescriptions

## Launch Focus: Driving Rapid Adoption and Prescription Momentum

![img-4.jpeg](img-4.jpeg)

![img-5.jpeg](img-5.jpeg)

Source: Symphony

13

impel
PHARMACEUTICALS

# Sales Force Expansion Allowing for Additional HCP Discussions Resulting in NBRx Growth

![img-6.jpeg](img-6.jpeg)

Source: Symphony NBRx data
* Excludes current vacancies (n=7)

14

Impel
PHARMACEUTICALS

# Trudhesa Adoption Showing Continued Growth

![img-7.jpeg](img-7.jpeg)

Source: Internal Pharmacy Data

15

Impel
PHARMACEUTICALS

# Increasing Reimbursement and Consistently High Refill Rates

Percent of Rx Shipments Reimbursed

![img-8.jpeg](img-8.jpeg)

Source: Internal Pharmacy Data

Trudhesa: Consistent, High Refill Rates

![img-9.jpeg](img-9.jpeg)

Source: Internal Pharmacy Data

16

impel
PHARMACEUTICALS

# Trudhesa Increasingly Being Added to Gepant Patients to Provide Additional Efficacy

Gepant Patient Claims Show ~60% Therapy Abandonment 90 Day Post Start

![img-10.jpeg](img-10.jpeg)

Source: Symphony Patient Level Claims Data (YTD Aug'22)

~40% of Trudhesa Patients Being Either Switched From or Added to Gepants

![img-11.jpeg](img-11.jpeg)

Source: Symphony Patient Level Claims Data

~71% of Trudhesa Patients Being Added to Existing Therapy

![img-12.jpeg](img-12.jpeg)

Source: Symphony Patient Level Claims Data

17

impel
PHARMACEUTICALS

# Pipeline Growth Opportunities

![img-13.jpeg](img-13.jpeg)

18

Impel
PHARMACEUTICALS

# INP105 - Potential to Provide Rapid and Non-Traumatic Acute Treatment of Agitation and Aggression in Autism

![img-14.jpeg](img-14.jpeg)

- Over 100m annual agitation/aggression episodes from ~600k children and adolescents with ASD
- Vast majority of episodes are not treated with PRN medications leaving HCP's to adjust daily/standing medications
  - Current options require daily dosing, tend to produce weight gain, and increase diabetes risk; require close monitoring
- PRN dosing of INP105 may provide the efficacy of olanzapine while sparing patients many of the tolerability and safety issues seen with daily use
- Caregiver administration brings control to families in home setting
  - Non-invasive administration when meds are needed
  - Episode may be aborted before escalation

Source: ZS Associates Market Research / Market Sizing (May'22)

19

impel
PHARMACEUTICALS

# INP105 - Acute Treatment of Agitation in Autism

INP105 - SIMILAR PK TO OLANZAPINE INJECTION, BUT FASTER TO PEAK BLOOD LEVELS

Phase 1 PK Profile vs. IM

Rapid Tmax, Cmax and AUC of INP105 matches 5mg IM olanzapine

![img-15.jpeg](img-15.jpeg)

*Nominal times used for mean plot

Phase 1 Conclusions

- INP105 enables rapid systemic absorption without an injection
- INP105 was well tolerated and led to similar exposure and faster plasma uptake than IM injection
- INP105 had rapid onset of action observed in healthy volunteers
- INP105 may be the first rapid acting olanzapine to treat agitation in multiple indications

![img-16.jpeg](img-16.jpeg)

CALM 201 Clinical Study

Objective

CALM 201 studies INP105 in adolescents with Autism

Study Design

Single dose, placebo controlled, double blind study of safety and efficacy through multiple scales

Study Timelines

- Study initiation - July 2022
- Pilot phase completed - Q4 2022
- Last Patient, Last Visit - Q2 2023
- Full Study Results - 2H 2023

20

impel
PHARMACEUTICALS

# Overall Business Summary

![img-0.jpeg](img-0.jpeg)

21

Impel
PHARMACEUTICALS

# Corporate Business Overview - Summary

- **Trudhesa growth continues with an expanding high value prescriber base**
  - Normalized Total Rx’s increased in Q4 by ~18% vs. Q3
  - Trudhesa nTRx share of the acute branded market now over ~4% among prescribers
  - Increased cumulative LTD Trudhesa prescribers by ~23% vs. Q3
- **Field force expansion leading to improvement in leading indicators**
  - ~58% increase in normalized New Prescriptions in Q4 vs. Q2 (pre-expansion)
  - Increased efficiency leading to significant increases across both new and existing territories
- **Stable GTN levers with net price evolution in clear view with quickstart/bridge adjustments**
- **INP105 Phase IIa CALM 201 study progressing with results expected 2H2023**

22

Impel
PHARMACEUTICALS

# Appendix

23

Impel
PHARMACEUTICALS

# Surveyed Trudhesa Patients Provide High Rating to Key Brand Attributes and Saw Trudhesa as Better Option vs Prior Abortive Therapy*

## Trudhesa Patient Experience

Agree/Strongly Agree

![img-1.jpeg](img-1.jpeg)

## Trudhesa Performance vs Prior Abortive Therapy

Agree/Strongly Agree

![img-2.jpeg](img-2.jpeg)

* Source: Ipsos Patient Survey via Digital Pharmacy

24

**impel**  
PHARMACEUTICALS

# Trudhesa Increasingly Being Added to Gepant Patients to Provide Additional Efficacy

![img-3.jpeg](img-3.jpeg)

Source: Symphony Patient Level Claims Data (YTD Aug'22)

![img-4.jpeg](img-4.jpeg)

Source: Symphony Patient Level Claims Data

25

impel
PHARMACEUTICALS

# Anticipate Robust Gepant Market Growth Thru 2025

![img-5.jpeg](img-5.jpeg)

- Gepant Market to reach ~4.5m nTRx's in 2023 and increase to ~8m in 2025
- Nearly 1m Gepant Patients in 2023
- Trudhesa share in 2022 = ~1%

Source: Symphony Health

26

Impel
PHARMACEUTICALS

# Neurologists Project a Sizable Increase in Trudhesa's Brand Share

![img-6.jpeg](img-6.jpeg)

![img-7.jpeg](img-7.jpeg)

Quantitative data collected from 75 US neurologists between June 1st and June 5th, 2022
Qualitative data collected from 8 US neurologists between June 13th and 17th, 2022

![img-8.jpeg](img-8.jpeg)

27